Volume 29, Issue 1 pp. 40-42
Full Access

Combined therapy with growth hormone and oxandrolone in adolescent girls with Turner syndrome

P. W. LU

Corresponding Author

P. W. LU

Robert Vines Growth Research Centre, Royal Alexandra Hospital for Children, Sydney, New South Wales, Australia

Dr P. W. Lu, Robert Vines Growth Research Centre, Royal Alexandra Hospital for Children, PO Box 34, Camperdown, NSW 2050, Australia.Search for more papers by this author
C. T. COWELL

C. T. COWELL

Robert Vines Growth Research Centre, Royal Alexandra Hospital for Children, Sydney, New South Wales, Australia

Search for more papers by this author

P. W. Lu, MB, MM(Syd), Research Fellow in Endocrinology. C. T. Cowell, MB, BS, FRACP, FRCP(C), Senior Paediatric Endocrinologist, Director of Robert Vines Growth Research Centre.

Abstract

Five adolescent girls with Turner syndrome (mean age 13.9 years, mean bone age 12.0 years) were treated with both recombinant human growth hormone (rhGH) and oxandrolone for 2 years with an average increment in height of 13.4 cm. The mean bone age advanced by only 1.2 years, providing an increase in the mean estimated mature height of 9.2 cm. We conclude that rhGH and oxandrolone benefit older teenagers with Turner syndrome because of an increased growth rate with slow progression of skeletal maturation.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.